AN2 Therapeutics, Inc.

TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.

Paratek PharmaceuticalsPharmaceuticalsUnited States

67% match

Paratek Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for complex medical conditions, focusing on infectious diseases and antimicrobial resistance. The company's product portfolio includes NUZYRA, an antibiotic for bacterial infections, and XHANCE, a nasal spray for chronic rhinosinusitis. These treatments are designed to serve adult patients with significant unmet medical needs.

AicurisPharmaGermany

67% match

AiCuris Anti-infective Cures AG is a biopharmaceutical company headquartered in Wuppertal, Germany. The company specializes in the research and development of innovative, life-saving anti-infective therapies designed to address critical needs in immunocompromised patients.

Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.

Venatorx PharmaceuticalsPharmaceuticalsUnited States

66% match

Venatorx Pharmaceuticals, Inc. is a pharmaceutical manufacturing company based in Malvern, Pennsylvania, focused on the discovery and development of novel anti-infective treatments.

Turn Therapeutics Inc.TTRX · PharmaceuticalsWestlake Village, United States

65% matchPublic

Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.